Big biopharma and venture investors moved over the holidays to shore up oncology and kinase pipelines. AbbVie agreed to pay $100 million upfront for an option to license Zejing’s DLL3-targeting trispecific outside China, with up to $1.07 billion in milestones; Gilead paid $25 million up front for Repare’s Polθ inhibitor RP-3467, a synthetic-lethality candidate. Separately, Blossomhill announced a Series B extension to advance its macrocyclic EGFR and CLK inhibitor programs. The transactions signal continued appetite for oncology and targeted-kinase assets despite a cautious market.